153 related articles for article (PubMed ID: 36248273)
1. Association of Urinary Pentosidine Levels With the Risk of Fractures in Patients With Severe Osteoporosis: The Japanese Osteoporosis Intervention Trial-05 (JOINT-05).
Tanaka S; Saito M; Hagino H; Mori S; Nakamura T; Ohta H; Sone T; Takahashi K; Mitomo Y; Sugimoto T; Soen S;
JBMR Plus; 2022 Oct; 6(10):e10673. PubMed ID: 36248273
[TBL] [Abstract][Full Text] [Related]
2. Urinary pentosidine and plasma homocysteine levels at baseline predict future fractures in osteoporosis patients under bisphosphonate treatment.
Shiraki M; Kuroda T; Shiraki Y; Tanaka S; Higuchi T; Saito M
J Bone Miner Metab; 2011 Jan; 29(1):62-70. PubMed ID: 20458602
[TBL] [Abstract][Full Text] [Related]
3. Design of a randomized trial of teriparatide followed by alendronate: Japanese Osteoporosis Intervention Trial-05 (JOINT-05).
Tanaka S; Mori S; Hagino H; Sugimoto T
J Bone Miner Metab; 2020 May; 38(3):412-417. PubMed ID: 31894491
[TBL] [Abstract][Full Text] [Related]
4. Urinary pentosidine level is associated with the risk of fracture in community-dwelling older adults: a prospective observational study.
Hagino H; Moriwaki K; Wada T; Osaki M; Nagashima H; Matsumoto H
Osteoporos Int; 2023 Oct; 34(10):1703-1709. PubMed ID: 37291359
[TBL] [Abstract][Full Text] [Related]
5. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.
Black DM; Schwartz AV; Ensrud KE; Cauley JA; Levis S; Quandt SA; Satterfield S; Wallace RB; Bauer DC; Palermo L; Wehren LE; Lombardi A; Santora AC; Cummings SR;
JAMA; 2006 Dec; 296(24):2927-38. PubMed ID: 17190893
[TBL] [Abstract][Full Text] [Related]
6. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.
Saag KG; Zanchetta JR; Devogelaer JP; Adler RA; Eastell R; See K; Krege JH; Krohn K; Warner MR
Arthritis Rheum; 2009 Nov; 60(11):3346-55. PubMed ID: 19877063
[TBL] [Abstract][Full Text] [Related]
7. Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT) - 02.
Orimo H; Nakamura T; Fukunaga M; Ohta H; Hosoi T; Uemura Y; Kuroda T; Miyakawa N; Ohashi Y; Shiraki M;
Curr Med Res Opin; 2011 Jun; 27(6):1273-84. PubMed ID: 21554143
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for incident vertebral fractures in osteoporosis pharmacotherapy: a 2-year, prospective, observational study.
Hagino H; Uemura Y; Mori S; Sone T; Ohta H; Nakamura T
J Bone Miner Metab; 2021 Jul; 39(4):668-677. PubMed ID: 33738617
[TBL] [Abstract][Full Text] [Related]
9. Nonenzymatic collagen cross-links induced by glycoxidation (pentosidine) predicts vertebral fractures.
Shiraki M; Kuroda T; Tanaka S; Saito M; Fukunaga M; Nakamura T
J Bone Miner Metab; 2008; 26(1):93-100. PubMed ID: 18095070
[TBL] [Abstract][Full Text] [Related]
10. The association of urinary pentosidine levels with the prevalence of osteoporotic fractures in postmenopausal women.
Shiraki M; Kashiwabara S; Imai T; Tanaka S; Saito M
J Bone Miner Metab; 2019 Nov; 37(6):1067-1074. PubMed ID: 31214839
[TBL] [Abstract][Full Text] [Related]
11. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
Delmas PD; Licata AA; Reginster JY; Crans GG; Chen P; Misurski DA; Wagman RB; Mitlak BH
Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890
[TBL] [Abstract][Full Text] [Related]
12. Indirect comparison of teriparatide, denosumab, and oral bisphosphonates for the prevention of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis.
Zhang L; Pang Y; Shi Y; Xu M; Xu X; Zhang J; Ji L; Zhao D
Menopause; 2015 Sep; 22(9):1021-5. PubMed ID: 25944523
[TBL] [Abstract][Full Text] [Related]
13. Urinary levels of pentosidine and the risk of fracture in postmenopausal women: the OFELY study.
Gineyts E; Munoz F; Bertholon C; Sornay-Rendu E; Chapurlat R
Osteoporos Int; 2010 Feb; 21(2):243-50. PubMed ID: 19421701
[TBL] [Abstract][Full Text] [Related]
14. Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
Saag KG; Shane E; Boonen S; Marín F; Donley DW; Taylor KA; Dalsky GP; Marcus R
N Engl J Med; 2007 Nov; 357(20):2028-39. PubMed ID: 18003959
[TBL] [Abstract][Full Text] [Related]
15. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
Biermasz NR; Hamdy NA; Janssen YJ; Roelfsema F
J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
[TBL] [Abstract][Full Text] [Related]
16. Three-year experience with combined treatment with alendronate and alfacalcidol in Japanese patients with severe bone loss and osteoporotic fracture.
Iwamoto J; Sato Y; Uzawa M; Takeda T; Matsumoto H
Ther Clin Risk Manag; 2011; 7():257-64. PubMed ID: 21753888
[TBL] [Abstract][Full Text] [Related]
17. Effect of alendronate for reducing fracture by FRAX score and femoral neck bone mineral density: the Fracture Intervention Trial.
Donaldson MG; Palermo L; Ensrud KE; Hochberg MC; Schousboe JT; Cummings SR
J Bone Miner Res; 2012 Aug; 27(8):1804-10. PubMed ID: 22492479
[TBL] [Abstract][Full Text] [Related]
18. Real-World Effectiveness of Osteoporosis Medications in France: A Nationwide Cohort Study.
Bosco-Lévy P; Briot K; Mehsen-Cetre N; O'Kelly J; Désaméricq G; Abouelfath A; Lassalle R; Grelaud A; Grolleau A; Blin P; Droz-Perroteau C
JBMR Plus; 2023 Sep; 7(9):e10789. PubMed ID: 37701145
[TBL] [Abstract][Full Text] [Related]
19. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study.
Garnero P; Sornay-Rendu E; Claustrat B; Delmas PD
J Bone Miner Res; 2000 Aug; 15(8):1526-36. PubMed ID: 10934651
[TBL] [Abstract][Full Text] [Related]
20. Increased Risk of Tooth Loss in Postmenopausal Women With Prevalent Vertebral Fractures: An Observational Study.
Taguchi A; Urano T; Nakamura Y; Shiraki M
JBMR Plus; 2023 Dec; 7(12):e10822. PubMed ID: 38130772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
